Accordingly, it is reasonable to hypothesize that abolishing IL-6 or targeting its associated signaling may reinforce the tumor-suppressive activities of WT p53, thereby enhancing cancer cell responsiveness to genotoxic anticancer drugs. The gene discussed is TP53; the disease is neoplasm.